SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models

AXL‐mediated activation of aberrant tyrosine kinase drives various oncogenic processes and facilitates an immunosuppressive microenvironment. We evaluated the anti‐tumor and anti‐metastatic activities of SKI‐G‐801, a small‐molecule inhibitor of AXL, alone and in combination with anti‐PD‐1 therapy.

[1]  Sung-Bae Kim,et al.  Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Yu‐quan Wei,et al.  AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications , 2019, Molecular Cancer.

[3]  P. thor Straten,et al.  TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting , 2019, Cancer Immunology, Immunotherapy.

[4]  Jae Cheol Lee,et al.  AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis , 2018, Oncology reports.

[5]  A. Broeks,et al.  Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma , 2018, Nature Medicine.

[6]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[7]  Gan‐Lin Zhang,et al.  Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation , 2018, Oncology letters.

[8]  W. Cui,et al.  Function of Axl receptor tyrosine kinase in non-small cell lung cancer. , 2017, Oncology letters.

[9]  Ross A Soo,et al.  De-novo and acquired resistance to immune checkpoint targeting. , 2017, The Lancet. Oncology.

[10]  R. Huang,et al.  AXL-Driven EMT State as a Targetable Conduit in Cancer. , 2017, Cancer research.

[11]  P. Ma,et al.  AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases , 2017, Journal of Cancer Research and Clinical Oncology.

[12]  Jing Wang,et al.  Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer , 2017, Clinical Cancer Research.

[13]  Thomas R. Cox,et al.  Pre-metastatic niches: organ-specific homes for metastases , 2017, Nature Reviews Cancer.

[14]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2017, Cell.

[15]  H. Stehr,et al.  Reprogramming the immunological microenvironment through radiation and targeting Axl , 2016, Nature Communications.

[16]  Jianguang Wang,et al.  Expression of Axl and its prognostic significance in human breast cancer , 2016, Oncology letters.

[17]  M. Smyth,et al.  Abstract B115: Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease , 2016 .

[18]  A. Banerjee,et al.  Effector, Memory, and Dysfunctional CD8+ T Cell Fates in the Antitumor Immune Response , 2016, Journal of immunology research.

[19]  P. Tamboli,et al.  Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma , 2016, Oncogene.

[20]  J. van Rheenen,et al.  Intravital Insights into Heterogeneity, Metastasis, and Therapy Responses. , 2016, Trends in cancer.

[21]  Fan Wang,et al.  Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition , 2016, Theranostics.

[22]  I. Gill,et al.  Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma , 2015, British Journal of Cancer.

[23]  R. Salgia,et al.  AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma , 2015, Clinical Cancer Research.

[24]  K. Davies,et al.  The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer , 2014, Nature Reviews Cancer.

[25]  Janfeng Wang,et al.  The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma. , 2014, International journal of clinical and experimental pathology.

[26]  Zhengming Chen,et al.  Axl receptor tyrosine kinase expression in breast cancer , 2014, Journal of Clinical Pathology.

[27]  Y. Jeng,et al.  Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. , 2014, Carcinogenesis.

[28]  J. Herz,et al.  An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo. , 2014, The Journal of clinical investigation.

[29]  Melissa Mallon.  Data Curation , 2012 .

[30]  K. Tai,et al.  Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1 , 2008, Oncogene.

[31]  P. Elvin,et al.  Tumour invasion and metastasis: challenges facing drug discovery. , 2005, Current opinion in pharmacology.

[32]  M. Blostein,et al.  Intracellular signaling pathways involved in Gas6-Axl-mediated survival of endothelial cells. , 2004, American journal of physiology. Heart and circulatory physiology.

[33]  R. Boot-Handford,et al.  Receptor Tyrosine Kinase Axl Modulates the Osteogenic Differentiation of Pericytes , 2003, Circulation research.

[34]  M. Hung,et al.  Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis , 2002, Oncogene.

[35]  R. Reis,et al.  Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. , 2018, Urologic oncology.

[36]  Xin-Yun Huang,et al.  Mouse models for tumor metastasis. , 2012, Methods in molecular biology.